Pharmaceuticals

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Landscape: Trends and Market Share to 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Current and Projected Market Size of the Duchenne Muscular Dystrophy (DMD) Therapeutics Industry?#_x000D_

In the past few years, there has been a consistent growth observed in the donepezil market size. From $1 billion in 2024, it is projected to amplify to $1.04 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.1%. This expansion during the historic period is primarily driven by factors such as the surge in Alzheimer’s disease cases, the expanding elderly population, increased government expenditure and initiatives, heightened awareness about neurodegenerative disorders, and the escalating demand for top-grade nucleic acid samples._x000D_

_x000D_

The donepezil market is anticipated to witness stable expansion in the coming years. The market’s valued is projected to attain “$1.24 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 4.5%. This growth in the forecast period can be contributed to the surge in healthcare spending, increased attention towards early detection of Alzheimer’s, the rising need for combination therapies, hefty investment in healthcare infrastructure, and heightened awareness about neurodegenerative diseases. Key trends projected during this period encompass drug formulation and delivery method innovations, technological progression, the introduction of new dosage forms and formulations, the authorization of generic donepezil variants, and cutting-edge research facilities._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21174&type=smp_x000D_

_x000D_

#Which Factors Are Currently Driving The Growth Of The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?_x000D_

The Duchenne muscular dystrophy (DMD) therapeutics market is projected to grow due to the increasing quantity of clinical trials. Clinical trials involve the study of medical practices, treatments, and new drugs on human subjects to ascertain their safety, efficacy, and potential advantages. The growing number of clinical trials focused on treating Duchenne muscular dystrophy indicates persistent research, innovation, and a varied range of potential therapies. This would not only provide better results for patients, but also attract further investments, and accelerate the growth and availability of efficient treatments for Duchenne Muscular Dystrophy (DMD). For instance, in August 2023, Clinicaltrials.Gov, which is under the purview of The National Institutes Of Health (NIH), a U.S. government agency responsible for carrying out and supporting medical investigations, reported an increase in the number of registered clinical trials, rising to 464,218 from 399,496 in 2021 across all 50 U.S. states and 221 countries. Furthermore, it was noted that 142,700 studies (31% of the entire number) were registered in the U.S., while 248,310 studies (53% of the whole number) were logged in locations outside of the U.S. As such, the continuous growth in the number of clinical trials will contribute to the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market._x000D_

_x000D_

The donepezil market covered in this report is segmented – _x000D_

_x000D_

1) By Type: 5mg, 10mg, 23mg_x000D_

2) By Route Of Administration: Oral, Transdermal_x000D_

3) By Application: Hospitals, Clinics, Drugstore_x000D_

_x000D_

Subsegments:_x000D_

1) By 5mg: Immediate-Release 5mg, Orally Disintegrating 5mg _x000D_

2) By 10mg: Immediate-Release 10mg, Orally Disintegrating 10mg _x000D_

3) By 23mg: Extended-Release 23mg, Film-Coated 23mg_x000D_

_x000D_

#What Trends Are Currently Influencing Growth In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?#_x000D_

Renowned companies engaged in the donepezil market are prioritizing the development of novel, sophisticated technologies like the donepezil system. The objective is to enhance patient adherence and boost the efficacy of treatment via innovative formulations, such as extended-release. Donepezil serves as a scheme to the drug system or mode of action of donepezil, primarily utilized to treat Alzheimer’s disease and various forms of dementia. For example, Corium Innovation Inc., a biopharmaceutical company headquartered in the US, introduced a donepezil transdermal system (Adlarity) for the treatment of patients diagnosed with mild, moderate, or severe Alzheimer’s disease (AD) dementia in October 2022. The cutting-edge transdermal formulation of donepezil enables medication delivery directly through the skin, circumventing the digestive system. This strategy greatly lowers the potential for gastrointestinal side effects and provides a more manageable method of administration, conferring advantages to both Alzheimer’s patients and their caregivers._x000D_

_x000D_

#Who Are The Main Participants Shaping The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Landscape?#_x000D_

Major companies operating in the donepezil market are AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Inc., Intas Pharmaceuticals Ltd., Mylan NV, Sandoz Group AG, Hetero Drugs Ltd., Sun Pharmaceutical Inc., Eisai Co. Ltd., Cipla Ltd., Dr Reddy’s Laboratories, Apotex Inc., H Lundbeck A/S, Zydus Cadila, Amneal Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd, Alkem Laboratories Ltd., Jubilant Pharmova Ltd., Wockhardt Ltd., Luoxin Pharmaceuticals Group _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/donepezil-global-market-report_x000D_

_x000D_

#Which Region Currently Holds The Largest Share In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?#_x000D_

North America was the largest region in the donepezil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the donepezil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21174&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_